AdventRx Pharmaceuticals has entered into a multi-year agreement with Patheon under which Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the Phase III study of ANX-188 that AdventRx plans to initiate this year. ANX-188 is a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell dis...